Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Viracta Therapeutics, Inc. (VIRX) has issued a series of news releases that trace its evolution from an active clinical-stage precision oncology company to an organization in wind down. Company announcements describe a focus on virus-associated cancers, particularly Epstein-Barr virus (EBV)-positive lymphomas and solid tumors, and provide detailed updates on its lead product candidate, Nana-val, an all-oral combination of nanatinostat and valganciclovir.
News items have covered multiple aspects of Viracta’s development programs, including clinical data from the Phase 2 NAVAL-1 trial in relapsed or refractory EBV-positive lymphomas and from a Phase 1b/2 study in EBV-positive nasopharyngeal carcinoma and other advanced EBV-positive solid tumors. The company has reported positive antitumor activity and a generally well-tolerated safety profile for Nana-val in certain EBV-positive peripheral T-cell lymphoma (PTCL) populations, as well as productive regulatory interactions with the U.S. Food and Drug Administration regarding potential paths to registration.
Corporate and strategic developments are also documented in Viracta’s news flow. Releases describe resource reprioritizations, reductions in force, and a resizing of the board of directors as the company sought to conserve cash and focus on its EBV-positive lymphoma program. Later communications announce the closure of the pivotal NAVAL-1 trial while the board explores strategic alternatives, and ultimately, the termination of employees and a decision to wind down operations, with continued exploration of options for the development programs.
On Stock Titan’s VIRX news page, readers can review this sequence of clinical, regulatory, and corporate updates directly from Viracta’s public disclosures. This provides historical context on Nana-val’s development, Viracta’s precision oncology strategy in EBV-associated cancers, and the subsequent decisions to close trials, explore strategic alternatives, and wind down operations.
Viracta Therapeutics (Nasdaq: VIRX) announced significant advancements in its ongoing Phase 1b/2 trial of Nana-val for patients with EBV-positive solid tumors. The Safety Monitoring Committee approved the escalation to the second dose cohort after observing no dose-limiting toxicities to date. The trial focuses on patients with recurrent or metastatic nasopharyngeal cancer. Preliminary safety and efficacy data are expected by the second half of 2022. Additionally, a poster presentation summarizing the trial's design will occur at the ASCO Annual Meeting on June 6, 2022.
Viracta Therapeutics, a precision oncology firm focused on virus-associated cancers, will present at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 p.m. EDT. A live webcast of the presentation can be accessed on their Investors page, with an archive available for 30 days. Viracta's key product, an oral combination therapy called Nana-val, is being evaluated in pivotal trials for treating relapsed/refractory Epstein-Barr virus-positive lymphomas and related cancers.
Viracta Therapeutics (Nasdaq: VIRX) announced the grant of non-qualified stock options to a new non-executive employee for 110,000 shares at an exercise price of $1.91 per share. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. This grant falls under the 2021 Inducement Equity Incentive Plan, aimed at incentivizing new hires. Viracta is focused on precision oncology, particularly targeting virus-associated malignancies, with its lead product candidate, Nana-val, in active clinical trials.
Viracta Therapeutics, a precision oncology company focused on virus-associated malignancies, will present at key investor conferences this May. The first is the RBC Capital Markets 2022 Global Healthcare Conference on May 18, 2022, at 9:00 a.m. EDT, followed by the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:30 a.m. EDT. Both presentations will feature a fireside chat format. Investors can access live webcasts on the Viracta website, available for 30 days post-event. Viracta's lead therapy, Nana-val, is in ongoing clinical trials targeting EBV-positive malignancies.
Viracta Therapeutics (Nasdaq: VIRX) reports significant clinical and financial updates for Q1 2022. The company continues global expansion of the NAVAL-1 trial for Nana-val in EBV-positive lymphoma, with updates on advancing cohorts expected in H2 2022. Preliminary safety and efficacy data for Nana-val in advanced EBV-positive solid tumors are also anticipated later this year. As of March 31, 2022, cash and cash equivalents stand at $92.2 million, projected to fund operations into mid-2024. The Q1 net loss was approximately $10.5 million, a notable reduction from the previous year's loss.
On April 20, 2022, Viracta Therapeutics (Nasdaq: VIRX) announced a webinar scheduled for April 27 at 11:00 AM EDT. The event will focus on Nana-val, a combination therapy of nanatinostat and valganciclovir, targeting advanced Epstein-Barr virus-positive solid tumors. Key opinion leader Ezra Cohen, MD, will present the current treatment landscape for nasopharyngeal carcinoma and discuss the urgent need for new treatments. Viracta's management will also provide updates on ongoing clinical trials for Nana-val, followed by a Q&A session.
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced its participation at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. EDT. The presentation will focus on the company's precision oncology initiatives targeting virus-associated malignancies, particularly its lead product candidate, Nana-val. This all-oral therapy combines nanatinostat and valganciclovir and is currently being evaluated in multiple trials for treating Epstein-Barr virus-positive lymphomas and nasopharyngeal carcinoma. A webcast of the presentation will be available on the Viracta website.
Viracta Therapeutics (Nasdaq: VIRX) announced the approval of non-qualified stock options for a new non-executive employee to purchase 200,000 shares at an exercise price of $3.04 per share, equal to the March 17, 2022 closing price. The options will vest over four years, with 25% vesting after one year and the remainder in monthly increments, contingent on continuous employment. This grant is part of Viracta's 2021 Inducement Equity Incentive Plan, designed to attract new talent consistent with Nasdaq Listing Rule 5635(c)(4).
Viracta Therapeutics (NASDAQ: VIRX) announced participation in the 32nd Annual Oppenheimer Healthcare Conference on March 16, 2022, at 10:40 a.m. ET. The event will feature a fireside chat with company leadership, highlighting their focus on precision oncology targeting virus-associated malignancies. The webcast will be available on their website under 'Events and Webcasts' and archived for 30 days. Viracta's lead candidate, Nana-val, is currently in clinical trials for treating Epstein-Barr virus-positive lymphomas and other related cancers.
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology firm, announced that CEO Dr. Ivor Royston will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 5:00 p.m. ET. The presentation can be accessed via webcast on the Investors section of Viracta's website, with an archive available for 60 days. Viracta focuses on virus-associated malignancies, evaluating its investigational drug nanatinostat in pivotal trials for Epstein-Barr virus-positive lymphoma and other cancers.
FAQ
What is the current stock price of Viracta Therapeutics (VIRX)?
What is the market cap of Viracta Therapeutics (VIRX)?
